long half life drug bioequivalence study design [Design Issues]

posted by ssussu – China, 2017-08-16 13:45 (2417 d 02:00 ago) – Posting: # 17690
Views: 9,252

Dear all,
I have questions on the BE study design of long half life drug, please kindly give me some advice. According to FDA GL:
You can use Cmax and a suitably truncated AUC to characterize peak and total drug exposure, respectively. For drugs that demonstrate low intrasubject variability in distribution and clearance, you can use an AUC truncated at 72 hours (AUC0-72 hr) in place of AUC0–t or AUC0–inf.
The question is
Should I just need to design the sampling time to 72hr or need to longer than 72hr?
If I just sampling for 72hr, how can I prove the drug is a long half life drug?

Best regards!

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
112 visitors (0 registered, 112 guests [including 7 identified bots]).
Forum time: 14:46 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5